Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADAM metallopeptidase with thrombospondin type 1 motif 19 (ADAMTS19)
- Target
- ADAMTS19
- Molecular classification
- Enzyme, Metzincin metallopeptidase, Extracellular matrix (ECM) protease
01
Overview
ADAM metallopeptidase with thrombospondin type 1 motif 19 (ADAMTS19) is a secreted zinc-dependent metalloproteinase belonging to the ADAMTS family, characterized by a multidomain structure including a metalloprotease domain and multiple thrombospondin type 1 motifs. These proteins primarily regulate extracellular matrix (ECM) composition by cleaving matrix proteins such as procollagen and proteoglycans, and contribute to tissue morphogenesis and remodeling. While the specific substrates and functions of ADAMTS19 have not yet been fully defined, it shares high sequence similarity with ADAMTS16 and may participate in developmental or disease processes involving the heart and connective tissue. Dysregulation of ADAMTS family members is implicated in a variety of pathological conditions, including cardiac valvular disease, arthritis, and cancer, positioning these enzymes as potential therapeutic targets. However, direct drugs or biomarker applications for ADAMTS19 are yet to emerge in clinical practice.
- Other names
- A disintegrin and metalloproteinase with thrombospondin motifs 19ADAMTS19ADAM-TS 19ADAM-TS19ADAMTS-19CVDP2A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motif, 19
02
Mechanism of action
null
03
Biological functions
Extracellular matrix remodelingTissue morphogenesisPossible roles in angiogenesis and apoptosisPotential involvement in cell-cell interactions
04
Disease associations
Cardiac valvular dysplasiaPotential roles in cancer, arthritis, atherosclerosis, and other pathologies
05
Safety considerations
Possible risks associated with ECM proteinase inhibitionTherapeutic challenge: functional redundancy and compensation within ADAMTS family
Beyond the preview
Go deeper on ADAM metallopeptidase with thrombospondin type 1 motif 19 (ADAMTS19).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAM metallopeptidase with thrombospondin type 1 motif 19 (ADAMTS19).